RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Genes & Genomics

• Publication date

  2022-02-11

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s13258-022-01217-0PMID 35147897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer statistics, 2019

  2019cited by this paper
• Regulation of Rho GTPases by RhoGDIs in Human Cancers

  2019cited by this paper
• Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line via a RhoGDI2/Rac1/NF-κB Signaling Pathway

  2018cited by this paper
• Targeting Rac and Cdc42 GTPases in Cancer.

  2018cited by this paper
• The Rac GTPase in Cancer: From Old Concepts to New Paradigms.

  2017cited by this paper
• Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma

  2017cited by this paper
• Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability

  2016cited by this paper
• Regulating Rho GTPases and their regulators

  2016cited by this paper
• An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

  2016cited by this paper
• Overexpression of RhoGDI2 correlates with the progression and prognosis of pancreatic carcinoma.

  2015cited by this paper
• RhoGDI2 up-regulates P-glycoprotein expression via Rac1 in gastric cancer cells

  2015cited by this paper
• Rac1 GTPase in pancreatic cancer

  2015cited by this paper
• Gemcitabine resistance in pancreatic ductal adenocarcinoma.

  2015cited by this paper
• Molecular mechanisms of epithelial–mesenchymal transition

  2014influential reference
• VEGF‐C mediates RhoGDI2‐induced gastric cancer cell metastasis and cisplatin resistance

  2014cited by this paper
• Diagnosis and management of pancreatic cancer.

  2014cited by this paper
• RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells

  2014cited by this paper
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

  2014cited by this paper
• 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells

  2013cited by this paper
• Diagnosis and management of pancreatic cancer

  2013cited by this paper
• The epigenetics of epithelial-mesenchymal plasticity in cancer

  2013cited by this paper
• Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.

  2012cited by this paper
• Early requirement of Rac1 in a mouse model of pancreatic cancer.

  2011cited by this paper
• RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.

  2011cited by this paper
• Overexpression of RhoGDI2 Correlates with Tumor Progression and Poor Prognosis in Colorectal Carcinoma

  2011cited by this paper
• PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.

  2011cited by this paper
• RhoGDI2 as a therapeutic target in cancer

  2010cited by this paper
• ROLE OF RAC-1 DEPENDENT NADPH OXIDASE IN THE GROWTH OF PANCREATIC CANCER

  2010cited by this paper
• RhoGDI: A rheostat for the Rho switch.

  2010cited by this paper
• Regulation of RhoGTPase crosstalk, degradation and activity by RhoGDI1

  2010cited by this paper
• Involvement of RhoGDI2 in the resistance of colon cancer cells to 5-fluorouracil.

  2010cited by this paper
• Consensus transcriptome signature of perineural invasion in pancreatic carcinoma

  2009cited by this paper
• Silencing of D4-GDI Inhibits Growth and Invasive Behavior in MDA-MB-231 Cells by Activation of Rac-dependent p38 and JNK Signaling

  2009cited by this paper
• Rho GDP dissociation inhibitor 2 suppresses metastasis via unconventional regulation of RhoGTPases.

  2009cited by this paper
• RhoGDI2 Expression Is Associated with Tumor Growth and Malignant Progression of Gastric Cancer

  2009cited by this paper
• Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

  2008cited by this paper
• Loss of expression of LyGDI (ARHGDIB), a rho GDP‐dissociation inhibitor, in Hodgkin lymphoma *

  2007cited by this paper
• RhoGDI: multiple functions in the regulation of Rho family GTPase activities.

  2005cited by this paper
• Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer

  2004cited by this paper
• Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.

  2003cited by this paper
• Dissociation of GDP Dissociation Inhibitor and Membrane Translocation Are Required for Efficient Activation of Rac by the Dbl Homology-Pleckstrin Homology Region of Tiam*

  2003influential reference
• RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.

  2002cited by this paper
• Rho GTPases in cell biology

  2002cited by this paper
• Changes in gene expression during progression of ovarian carcinoma.

  2001cited by this paper
• Changes in gene expression during progression of ovarian carcinoma

  2000cited by this paper
• Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility.

  1995cited by this paper
• Ly-GDI, a GDP-dissociation inhibitor of the RhoA GTP-binding protein, is expressed preferentially in lymphocytes.

  1993cited by this paper
• cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper

• EMT and cancer stem cells: Drivers of therapy resistance and promising therapeutic targets.

  2025cites this paper
• The Dual Function of RhoGDI2 in Immunity and Cancer

  2023cites this paper